Associate Professor in Medicine-Hematology/Oncology, Northwestern University Medical School
Oncology
Dr. Jessica K. Altman, MD
|
|
Give Review
Dr. Jessica K. Altman works in the field of Oncology. He graduated from University of Pittsburgh School of Medicine. He received awards:"Meaningful Use Stage 1 Certification". Dr. Jessica K. Altman is a published physician as well. He has 64 publications published. The latest was: Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Jessica Altman accepts Medicare payments and is listed with Medicare.gov.
Publications
- Tamibarotene in patients with Acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
- Targeted therapy of Acute myeloid leukemia.
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with Acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
- Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on Acute myeloid leukemia precursors.
- International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia.
- Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic Leukemia: short- and long-term outcomes.
- F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lym...
- Contemporary Treatment of APL.
- Coexistence of PML-RARα and BCR-ABL in Acute promyelocytic leukemia.
- Identifying novel genes in chronic myeloid Leukemia.
- Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk Acute promyelocytic leukaemia may eliminate the need for maintenance...
- Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literature.
- Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
- Chronic myelogenous Leukemia, version 1.2014.
- Administration of ATRA to newly diagnosed patients with Acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.
- Acute Myeloid Leukemia, Version 2.2013.
- Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with Acute myeloid leukemia.
- Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors.
- Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acut...
- Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reDuctase inhibitors.
- AKT is a therapeutic target in Myeloproliferative neoplasms.
- Next generation of mammalian target of rapamycin inhibitors for the treatment of Cancer.
- Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on Acute myeloid leukemia precursors.
- Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses.
- Tyrosine kinase inhibition in Acute myeloid leukemia.
- Sprouty Proteins Are Negative Regulators of Interferon (IFN) Signaling and IFN-inducible Biological Responses.
- New strategies in Acute myeloid leukemia: redefining prognostic markers to guide therapy.
- Statin-dependent activation of protein kinase Cδ in Acute promyelocytic leukemia cells and induction of leukemic cell differentiation.
- An overview of the mTOR pathway as a target in Cancer therapy.
- "Boldness be my friend" (Shakespeare; Cymbeline).
- Curing all patients with Acute promyelocytic leukemia: are we there yet?
- Antileukemic effects of AMPK activators on BCR-ABL expressing cells.
- Targeting AMPK in the treatment of malignancies.
- Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid Tumors and hematological malignancies.
- Protein kinase R (PKR) as mediator of the effects of IFN-gamma and TNF-alpha on normal and dysplastic hematopoiesis.
- Early death rate in Acute promyelocytic leukemia remains high despite all-trans retinoic acid.
- Targeting mTOR for the treatment of AML. New agents and new directions.
- Dual mTORC2/mTORC1 targeting results in potent suppressive effects on Acute myeloid leukemia (AML) progenitors.
- Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses.
- Autophagy is a critical mechanism for the inDuction of the antileukemic effects of arsenic trioxide.
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
- Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.
- How I treat Acute promyelocytic leukemia.
- Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or pri...
- Activation of protein kinase C{eta} by type I interferons.
- Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
- Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.
- Exploiting the mammalian target of rapamycin pathway in hematologic malignancies.
- Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.
- Curative strategies in Acute promyelocytic leukemia.
- The double hazard of thrombophilia and bleeding in Acute promyelocytic leukemia.
- Suppressive effects of statins on Acute promyelocytic leukemia cells.
- Charcot-Leyden crystals associated with Acute myeloid leukemia: case report and literature review.
- The coagulopathy of Acute promyelocytic leukaemia revisited.
- Prospects for mTOR targeting in adult T cell Leukemia.
- Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin''s Lymphoma.
- Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed Acute myeloid leukemia.
- Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
- Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.
- Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in Myelodysplastic syndromes.
- Renal cell carcinoma and Acute promyelocytic leukemia: a nonrandom association?
- Acute myeloid leukemia.
- Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells.
Schools
University of Pittsburgh School of Medicine
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Assurant Health
- Bakery & Confectionary Union Plan
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Health and Life PPO
- Platinum PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- Group Health Cooperative
- Medicare Advantage PFFS
- HealthLink PPO
- Choice Care PPO
- Medicare MCR
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Pipefitters
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- Meaningful Use Stage 1 Certification
Education
-
McGaw Medical Center of Northwestern University -
University of Chicago -
University of Pittsburgh School of Medicine
Hospital
-
Northwestern Memorial Hospital -
Jesse Brown Veterans Affairs Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Ann M. Mauer, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Irfan A. Mirza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Russell Z. Szmulewitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy M. Kuzel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. K J. Philip, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip Bonomi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marta Batus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hau Kwaan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silviya V. Velinova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hongtao Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Mulshine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander N. Shoushtari, MD |
|
|
Dr. Amikar Sehdev, MD |
|
|
Dr. Lisa Boggio, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth S. Cohen, MD |
|
|
Dr. Santiago F. Moscoso Martinez, MD |